Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3949/ccjm.76c.03002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: With the world population aging, the number of individuals living with dementia is expected to increase significantly. Vaccination against herpes zoster (HZ) with the live-attenuated zoster vaccine (ZVL) was associated with a lower risk of being diagnosed with dementia in previous studies. We aimed to determine whether the recombinant zoster vaccine (RZV) immunization is also associated with a reduced risk of dementia diagnosis.
View Article and Find Full Text PDFChallenges and Opportunities for Adult Vaccine Coverage: Insights for Healthcare Professionals Focusing on Herpes Zoster in Mexico.
Vaccines (Basel)
December 2024
GSK México, Torre Mitikah Piso 19 y 20, Circuito Interior Avenida Río Churubusco 601, Col. Xoco. Alc. Benito Juárez, Mexico City 03330, Mexico.
Herpes zoster (HZ) is a common disease in older adults and immunocompromised patients, and is frequently associated with long-term complications that impact quality of life. Fortunately, more than one vaccine against HZ is now available in Mexico. Two expert consensus groups discussed adult vaccination strategies in Mexico, focusing on HZ in older adults and immunocompromised individuals; their insights are reported here.
View Article and Find Full Text PDFThe Herpes Zoster Patient Pathway and Gaps in Current Vaccination Guidelines in Southeast Asia: Summary of a Zoster Experts' Network Scientific Workshop.
Vaccines (Basel)
December 2024
GSK, Ho Chi Minh City 70000, Vietnam.
The burden of herpes zoster (HZ) is recognized worldwide; however, there is seemingly limited information on incidence and vaccination practices in Southeast Asia (SEA). A scientific workshop was held by the Zoster Experts' Network to exchange and consolidate insights on the burden of HZ and the patient pathway in SEA. The workshop included practicing clinical experts and public health specialists/epidemiologists from Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
View Article and Find Full Text PDFmRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.
Vaccines (Basel)
December 2024
Internal Medicine, Faculty of Medicine and Surgery, Unicamillus, International School of Medicine, 00131 Rome, Italy.
Unlabelled: mRNA vaccines represent a milestone in the history of vaccinology, because they are safe, very effective, quick and cost-effective to produce, easy to adapt should the antigen vary, and able to induce humoral and cellular immunity.
Methods: To date, only two COVID-19 mRNA and one RSV vaccines have been approved. However, several mRNA vaccines are currently under development for the prevention of human viral (influenza, human immunodeficiency virus [HIV], Epstein-Barr virus, cytomegalovirus, Zika, respiratory syncytial virus, metapneumovirus/parainfluenza 3, Chikungunya, Nipah, rabies, varicella zoster virus, and herpes simplex virus 1 and 2), bacterial (tuberculosis), and parasitic (malaria) diseases.
Public Awareness and Willingness to Vaccinate Against Herpes Zoster: A Nationwide Cross-Sectional Study in Poland.
Vaccines (Basel)
December 2024
School of Public Health, Centre of Postgraduate Medical Education, 01-826 Warsaw, Poland.
Objectives: Herpes zoster (HZ), caused by varicella zoster virus reactivation, affects a significant portion of the population, leading to substantial morbidity. Vaccination is highly effective in preventing HZ, yet awareness and uptake remain low. This study assessed awareness and willingness to vaccinate against HZ in Poland following the introduction of a reimbursement policy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!